Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed

Merck (MRK) reported Q2 adjusted EPS of $2.13, surpassing consensus estimates, while revenues of $15.81 billion met expectations despite a 2% year-over-year decline. Flagship oncology product Keytruda saw sales rise 9% to $7.96 billion, outperforming, but Gardasil sales plunged 55% to $1.13 billion due to reduced China demand. The company narrowed its full-year 2025 revenue and adjusted EPS guidance, citing foreign exchange impacts and approximately $500 million in one-time payments, which led to a pre-market share decline.

Analysis

Merck's Q2 2025 results present a bifurcated performance narrative, where robust growth in the Oncology division is substantially offset by severe declines in Vaccines and pressure from one-time costs. While adjusted EPS of $2.13 surpassed the $2.01 consensus estimate, this was overshadowed by a 2% year-over-year revenue decline to $15.81 billion and a 7% drop in reported earnings. The company's core strength remains its Oncology franchise, with flagship product Keytruda posting a 9% sales increase to $7.96 billion, beating expectations. This was further supported by strong growth in alliance revenues from Lynparza (+15%) and the rapid uptake of new drugs like Winrevair, which grew sales to $336 million. Conversely, the Vaccines segment experienced a significant downturn, highlighted by a 55% plunge in Gardasil sales to $1.13 billion due to weakened demand in China. The market's negative reaction, evidenced by the pre-market share decline, is primarily linked to the narrowed full-year 2025 guidance. Despite a reduced foreign exchange headwind, the updated forecast incorporates approximately $500 million in charges for licensing and technology transfers, which pressures the EPS outlook and does not yet account for the impending $10 billion acquisition of Verona Pharma.

Key Decisions for Investors

• Investors should weigh the sustained, estimate-beating growth in the Oncology segment, led by Keytruda's 9% sales increase, against the sharp 55% decline in Gardasil revenue, which signals significant vulnerability in the Vaccines division.
• Factor in the impact of the narrowed 2025 guidance, as the market is clearly pricing in the negative effect of approximately $500 million in one-time payments that are compressing the EPS outlook.
• Given the stock's 15.5% year-to-date underperformance against its industry, assess whether current valuation sufficiently discounts the headwinds from Gardasil and one-time costs, or if the robust oncology pipeline presents a long-term value opportunity.
• Closely monitor the performance of new growth assets like Winrevair and the execution of the pending $10 billion Verona Pharma acquisition, as these are crucial to offsetting declines in legacy franchises and justifying future growth.